Diaxonhit, Boehringer Ingelheim Collaborate on Cancer Therapeutic Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Diaxonhit today announced an agreement with Boehringer Ingelheim to discover and characterize novel splice variants that potentially could be therapeutic targets for oncology.

Paris-based Diaxonhit will use its SpliceArray discovery platform to identify potential targets and then build a database of specific splice variants. Boehringer Ingelheim has the option to buy the rights to research, develop, and commercialize any targets discovered by Diaxonhit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, while another study provides new insights into pig domestication.

The blog Sartorial Science seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

DNA Sequencing is being used by researchers in California to survey fish and marine life as part of a conservation effort.